Biotech-Konzern: Biontech schließt drei deutsche Standorte – „Das ganze Staatsgeld liegt nun auf der Müllhalde“
Der Impfstoffhersteller findet keine Käufer für die Werke Idar-Oberstein, Marburg und Tübingen. 1800 Beschäftigte verlieren ihre Jobs. Ein früherer Wettbewerber schimpft – auch auf sich selbst.
Munich reports that three German Biontech sites – located in Idar-Oberstein, Marburg, and Tübingen – will close next year, marking the end of a month-long unsuccessful search for buyers. The trade publication had previously disclosed that Biontech had been unable to find potential purchasers for the facilities. Approximately 1,800 employees, comprising nearly a quarter of Biontech's workforce, are impacted by the closures.
In Tübingen, the closure is slated for the end of 2027, while Marburg and Idar-Oberstein are set to shut down at the beginning and end of 2028, respectively. Biontech attributed the failed acquisition search primarily to the challenging current market and investment climate. The company informed that additional severance packages had been agreed upon with the company's employee council to make the plant closures more socially acceptable.
Details of these compensation conditions were not provided by Biontech at the time. According to a spokesperson for the company, despite the "intensive efforts of all parties involved and a comprehensive sales process," the acquisition could not be realized. The Marburg plant had previously produced COVID-19 mRNA-based vaccines and plasmid DNA, a key raw material for mRNA vaccines and cell therapies.
Biontech had acquired the site from Swiss pharmaceutical giant Novartis and had made significant investments.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
